Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.10), FiscalAI reports.

Monopar Therapeutics Trading Down 0.8%

Shares of NASDAQ MNPR opened at $54.10 on Friday. The stock has a 50-day moving average price of $59.62 and a two-hundred day moving average price of $70.75. Monopar Therapeutics has a 12 month low of $26.06 and a 12 month high of $105.00. The company has a market cap of $361.39 million, a price-to-earnings ratio of -29.73 and a beta of 1.58.

Institutional Trading of Monopar Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MNPR. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its stake in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics during the fourth quarter valued at $65,000. JPMorgan Chase & Co. grew its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Monopar Therapeutics in the 2nd quarter worth about $80,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wall Street Zen lowered shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, January 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Morgan Stanley assumed coverage on Monopar Therapeutics in a report on Friday, January 9th. They set an "overweight" rating and a $115.00 price objective for the company. BTIG Research reaffirmed a "buy" rating and issued a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $107.00.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.